Proton magnetic resonance relaxation times T1 and T2 related to postmortem interval. An investigation on porcine brain tissue

In order to establish the validity of in vitro determination of the proton magnetic resonance (MR) relaxation times T1 and T2 in brain tissue at increasing time delay after death or operative excision, 81 brain tissue samples from 23 pigs were analyzed repeatedly. These samples, representing cortex, caudate nucleus and white matter, were studied microscopically after MR measurements. The T1 values exhibited no time dependence and the T2 values decreased slightly during the interval 2 to 90 hours after death. The samples were stored at +8 degrees C between the measurements. These results indicate that reliable in vitro measurements can be obtained in autopsy or surgical brain tissue specimens within 90 hours after death or excision, if handled properly.

An efficient approach for the selective isolation of specific transcripts from complex brain mRNA populations

As a consequence of the complexity of the nervous system, many characteristic proteins are only expressed at low levels, and their detection and purification often represents a formidable task. A strategy based on liquid hybridizations, which greatly facilitates the identification of the mRNA transcript for this kind of protein, is presented here. A ten-fold-enriched recombinant library was generated from cDNA transcribed from forebrain mRNA after subtraction of cerebellum sequences. Clones specific to forebrain could then be revealed with cerebellum subtracted probes, by colony hybridization. The use of selected cDNA populations greatly enhanced the sensitivity of the screening procedure; clones corresponding to transcripts present at an abundance as low as 0.0005% could still be detected. About 5% of specific clones were recognized with an enriched forebrain probe. Additional clones were revealed with subtracted probes from restricted areas such as cerebral cortex, brainstem, and hippocampus. The important features and potential applications of this approach are discussed.

Subchronic methamphetamine treatment selectively attenuates apomorphine-induced decrease in 3,4-dihydroxyphenylacetic acid level in mesolimbic dopaminergic regions

To investigate mechanisms of behavioral enhancement produced by repeated doses of amphetamines, the effects of apomorphine on 3,4-dihydroxyphenylacetic acid (DOPAC) and dopamine (DA) levels were examined in various brain regions of the rat on the 4th day of withdrawal after repeated administration of saline or methamphetamine (3 mg/kg, s.c.) twice daily for 14 days. Apomorphine (0.1 and 1.0 mg/kg, i.p.) produced a dose-dependent decrease in DOPAC levels and no effect on DA levels in the olfactory tubercle, nucleus accumbens, striatum, frontal and cingulate cortices of saline-treated animals. A decrease in DOPAC levels produced by a low dose of apomorphine was attenuated selectively in the olfactory tubercle and nucleus accumbens of methamphetamine-treated animals. A high dose of apomorphine produced a significant decrease in DOPAC levels in both regions. No such attenuation was obtained in the striatum and the frontal and cingulate cortices. These results suggest that subchronic methamphetamine may induce development of hyposensitivity of presynaptic DA receptors in the mesolimbic regions, which contribute to the behavioral enhancement produced by the drug.

Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations

The concentration of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in the human central nervous system was measured by radioimmunoassay in postmortem tissue of control patients and in those with histologically confirmed senile dementia of the Alzheimer type (SDAT). In the controls, CRF-LI was found in high concentrations in the hypothalamus and frontal cortex (Brodmann's area 10), in moderate concentrations in amygdala, substantia innominata, temporal and parietal cortex (Brodmann's areas 38 and 7), and the caudate nucleus, and in low concentrations in posterior hippocampus and nucleus accumbens. A marked reduction in the concentration of CRF-LI was observed in the frontal and temporal cortex (approximately 50%) as well as in the caudate nucleus (approximately 70%) in the SDAT group. The present findings suggest that neurons containing corticotropin-releasing factor are pathologically altered in SDAT, in addition to the previously described cholinergic and somatostatinergic neuronal degeneration.

Concentrations of immunoreactive thyrotropin-releasing hormone in the brain of patients with olivoponto-cerebellar atrophy

The concentrations of immunoreactive thyrotropin-releasing hormone (ir-TRH) in the brain of patients with olivoponto-cerebellar atrophy (OPCA) were studied. Three patients with OPCA and 8 non-central nervous system degenerative diseases were subjects in this study. Ir-TRH concentration in the brain was measured by radioimmunoassay. Ir-TRH was present in all parts of the dissected brain tissues (hypothalamus, frontal lobe, cerebellar cortex, olivary n., dentate n. and caudate n.) of patients with OPCA and non-central nervous system degenerative diseases. Ir-TRH concentration in the brain of case 1 and 2 was lower in the cerebellar cortex and olivary n., in contrast, ir-TRH concentration in case 3 was higher in the dentate n. The regions and the severity of pathological changes were different in each case of OPCA and changes in ir-TRH concentration in the brain did not always correlate with the severity of pathological changes. These findings suggest that changes in ir-TRH concentration in the brain of patients with OPCA may differ in each case, and may play some pathophysiological role in OPCA.

Pharmacological characterization of solubilized 5-HT1 serotonin binding sites from bovine brain

This report describes the pharmacologic characterization of [3H]serotonin binding activity solubilized from bovine frontal cortical membranes. The ability of a number of serotonin (5-HT) and lysergic acid diethylamide (LSD) analogs to compete with [3H]serotonin and D-[3H]LSD for binding to membrane and solubilized 5-HT1 sites has been investigated. The results indicate that the solubilized binding site is probably of the 5-HT1B type. Fifteen of the 21 compounds tested exhibit nearly identical affinity for membrane or solubilized 5-HT1 binding sites. However, some important differences were observed, and these may help elucidate the molecular structure of the binding site. In particular, some N-substituted tryptamine analogs show a markedly lower affinity for solubilized 5-HT1 sites compared to their binding to intact membranes. Further, the solubilized site does not distinguish stereoisomers of LSD: both D- and L-LSD bind to solubilized 5-HT1 sites with comparable high affinities, whereas D-LSD has a markedly higher affinity for the membrane 5-HT1 site. Methiothepin, which binds to the 5-HT1 site primarily through its amine groups, has virtually no affinity for the solubilized receptor, whereas it is quite potent at competing for [3H]serotonin binding to membrane sites. These observations lead to the conclusions that in bovine cortical membranes, the 5-HT1 site contains both indole and amine attachment sites. After solubilization, the indole attachment site retains its binding properties, but the amine attachment site has been significantly altered.(ABSTRACT TRUNCATED AT 250 WORDS)

Circadian changes in extracellular ascorbate in rat cortex, accumbens, striatum and hippocampus: correlations with motor activity

We have used linear sweep voltammetry with carbon-paste electrodes to monitor changes in the ascorbate signal simultaneously in rat frontal cortex, nucleus accumbens, striatum and hippocampus together with motor activity. The relative amplitude of the ascorbate signal recorded in the four regions corresponded to the relative density of excitatory amino acid (EAA) transmission determined by other methods; this result provides further evidence that the ascorbate signal may be used as an index of EAA release. Changes in motor activity were associated with changes in the ascorbate signal; linear regression analysis for motor activity versus the ascorbate signal revealed differences between the release of ascorbate in the four brain regions.

Laminar organization of cholinergic circuits in human frontal cortex in Alzheimer's disease and aging

Cholinergic enzyme activity (choline acetyltransferase, CAT; acetylcholinesterase, AChE) and muscarinic cholinergic receptor density were measured in frontal cortex (Brodmann's area 9) of normal patients over the life span and in brains of patients with Alzheimer's disease (AD). CAT, but not AChE activity, declined with normal aging. Significant loss of CAT and AChE activity occurred in the AD brains, but later onset AD was associated with less severe loss of frontal cortex CAT activity. The majority of normal CAT activity resided in lamina I, II, and upper lamina III; CAT loss in AD resulted in large losses from all depths, most notably the upper cortical layers. AChE did not precisely correspond to the localization of CAT; loss of AChE in AD was consistent across all six laminae. No differences were seen in muscarinic cholinergic receptor binding between AD and age-matched controls; the distribution of binding was equal in all layers of normal frontal cortex, and no laminar differences were detected in distribution of cholinergic receptors between normal and AD samples.

Behavioral investigation of the coexistence of substance P, corticotropin releasing factor, and acetylcholinesterase in lateral dorsal tegmental neurons projecting to the medial frontal cortex of the rat

Colocalization of substance P (SP), corticotropin releasing factor (CRF), and acetylcholinesterase (AChE) was detected by retrograde tracing and immunocytochemical staining in the nucleus tegmentalis dorsalis lateralis (ntdl) projecting to the medial frontal cortex (MFC), septum, and thalamus of the rat. The histochemical results suggest that SP and CRF coexist within a subpopulation of ntdl cholinergic neurons that project to a number of forebrain regions including the MFC. Behavioral studies of the effects of SP, CRF, and the cholinergic agonist, carbachol, employed microinjections into the MFC of rats. SP and CRF did not elicit any behavioral effects when administered alone. Carbachol (1-5 micrograms/side) produced a stereotyped motor behavior, consisting of rapid forepaw treading while in an upright posture, resembling "boxing." SP (1 micrograms/side) increased carbachol-induced "boxing." CRF (1-10 ng/side) decreased carbachol-induced "boxing." One possible functional significance of the coexistence of SP, CRF, and acetylcholinesterase, in neurons projecting to the medial frontal cortex in rats, appears to be a modulatory potentiation of cholinergic response by SP, and a modulatory inhibition of the cholinergic response by CRF.

[Correlation between the number of serotonin type 2 receptors in the frontal cortex of the mouse brain and the expressivity of serotonin-dependent head twitches]

The number of serotonin type 2 receptors (S2) was measured in the frontal cortex of mice belonging to 7 inbred strains using specific 3H-spiperone binding. In the same mice, measurements were also taken of the number of 5-hydroxytryptophan-induced (200 mg/kg i.p.) of head twitches (HT). A significant positive interspecific correlation was demonstrated between the number of S2 and HT. The conclusion is drawn that in the frontal cortex 3H-spiperone is bound to functionally active S2 and that the intensity of HT is largely controlled by the genetically determined number of S2 in the brain.

[Behavioral and neurochemical changes in pups prenatally treated with methamphetamine]

Changes in behavior and central neurotransmitters were examined in pups prenatally treated with methamphetamine (MAP). Compared with the control pups, the following results were obtained in MAP pups : 1) No change was found in the development of the circadian rhythm of spontaneous locomotor activity; 2) Spontaneous locomotor activity was decreased, while vertical activity was increased significantly in the postnatal period from the 24th to 27th days; 3) No sensitization to the test dose of MAP was found regardless of the prenatal repeated MAP treatment; 4) Dopamine concentration and the number of specific 3H-spiperone binding sites decreased in the frontal cortex. These findings indicate that prenatal treatment with MAP does not produce a lasting sensitization to MAP, whereas it does produce changes in behavior coupled with a neurochemical change in the frontal cortex.

An excitant amino acid projection from the medial prefrontal cortex to the anterior part of nucleus accumbens in the rat

High-affinity uptake of neurotransmitter substrates in synaptosome-containing homogenates and tissue concentrations of amino acids were examined in subcortical areas 5-6 days after bilateral N-methyl-D-aspartate lesions confined to rat medial prefrontal cortex. D-[3H]Aspartate (32% of control) and [3H] gamma-aminobutyric acid ( [3H]GABA) (60% of control) uptakes were significantly reduced in medial prefrontal cortex, whereas [3H]choline (110% of control) uptake was unchanged, suggesting the production of axon-sparing lesions. The uptake of D-[3H]aspartate (76% of control), but not of [3H]GABA or [3H]choline, was significantly reduced in nucleus accumbens, with no concomitant reduction in amino acid concentrations. When examined in serial coronal sections, reduced D-[3H]aspartate uptake was confined to the most anterior 500 micron of nucleus accumbens (67% of contralateral sample). No significant reductions of uptake or amino acid concentrations were observed in caudate putamen or ventral tegmental area. These results suggest a role for glutamate or aspartate as neurotransmitters in projections from medial prefrontal cortex to anterior nucleus accumbens. Medial prefrontal cortex may represent the major excitatory cortical input to the nucleus accumbens.

Brain gamma-aminobutyric acid and benzodiazepine receptor binding in dialysis encephalopathy

We measured gamma-aminobutyric acid (GABA) and benzodiazepine binding in autopsied frontal cortex of 8 patients dying with dialysis encephalopathy (DE). No alteration in [3H] GABA binding was observed. However, a mild reduction (-23%, P less than 0.05) of [3H] flunitrazepam-binding density was found in DE cortex. The magnitude of this reduction was similar to that observed in frontal cortex of amygdala-kindled rats [10]. We suggest that a reduction in benzodiazepine receptor number, in combination with markedly reduced GABA concentration in DE cerebral cortex may contribute to some of the clinical features (especially seizures) characteristically observed in this syndrome.

Muscarine-binding sites localized to cortical dopamine terminals

The effects of lesions to the mesocortical dopaminergic system on D2 dopamine receptors and muscarine receptors in the frontal cortex of the rat was examined. Four weeks following 6-hydroxydopamine lesioning of the ventral tegmental area, there was a 26% increase in the number of [3H]spiroperidol sites, and a 13% decrease in the number of [3H]oxotremorine-M sites in the frontal cortex, indicating a development of D2 receptor supersensitivity, as a result of deafferentation, and a loss of acetylcholine sites, as result of terminal degeneration. This demonstrates that in the frontal cortex, as in the striatum and nucleus accumbens, the activity of dopaminergic terminals may be partially modulated by cholinergic inputs.

Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease

Somatostatin receptor concentrations were measured in patients with Alzheimer's disease and controls. In the frontal cortex (Brodmann areas 6, 9, and 10) and temporal cortex (Brodmann area 21), the concentrations of somatostatin in receptors in the patients were reduced to approximately 50 percent of control values. A 40 percent reduction was seen in the hippocampus, while no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus. Scatchard analysis showed a reduction in receptor number rather than a change in affinity. Somatostatin-like immunoreactivity was significantly reduced in both the frontal and temporal cortex. Somatostatin-like immunoreactivity was linearly related to somatostatin-receptor binding in the cortices of Alzheimer's patients. These findings may reflect degeneration of postsynaptic neurons or cortical afferents in the patients' cerebral cortices. Alternatively, decreased somatostatin-like immunoreactivity in Alzheimer's disease might indicate increased release of somatostatin and down regulation of postsynaptic receptors.

Brain glycine levels following lithium toxicity: case report

A case is reported of a patient who died as a result of lithium toxicity. Brain lithium levels and changes in brain glycine levels are discussed.

Effects of phencyclidine administration on behavior and brain neurotensin-like immunoreactivity in rats

The effects of acute and chronic phencyclidine (PCP) administration on neurotensin-like immunoreactivity (NTLI) were investigated in discrete regions of rat brain. Both acute and chronic administration of PCP induced high locomotor activity, stereotypy and ataxia. On PCP administration, NTLI decreased significantly in the frontal cortex (Fc) alone. These results suggest that the decrease in NTLI in Fc is related to the behavioral abnormalities produced by PCP.

Sensitivity changes to dopaminergic agents in fine motor control of rhesus monkeys after repeated methamphetamine administration

Long-term behavioral and neurochemical effects of repeated methamphetamine (MA) administration were investigated in rhesus monkeys trained to perform a fine motor task requiring control of exerted force for a specified time. Rhesus monkeys were trained to extend their arms into a tube to press a lever with a force between 25 and 40 g for 5 sec in order to receive 1.5 ml of water. The effects of intramuscular administration of MA, apomorphine (APO) and haloperidol (HAL) on responding were compared before and after a 2-week period of repeated MA administration. During this period, MA was given in 4 divided doses starting at a total daily dose of 4 mg/kg/day and increasing to 40 mg/kg/day. Tolerance to MA, increased sensitivity to HAL and no consistent sensitivity change to APO were observed when dose-response functions were redetermined starting 1 month after the repeated MA administration. One month after these determinations were completed, the brains of the monkeys were analyzed for changes in monoamines. Significant depletions of dopamine in the caudate nucleus and serotonin in the frontal cortex were seen. It is hypothesized that the sensitivity changes to the drugs on performance were related to the dopamine depletion.

Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra

The effects of stress on dopamine (DA) metabolism in the mesencephalic DA cell body areas and DA terminal field regions were examined. Both mild footshock stress and exposure to a neutral stimulus previously paired with footshock resulted in a selective increase in the levels of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the prefrontal cortex as has been previously reported. Footshock stress also resulted in a slight but significant increase in DOPAC levels in the olfactory tubercles. DOPAC levels were selectively increased in the A10 cell body area (ventral tegmental area) but not A9 region (substantia nigra) by both footshock and the conditioned stress paradigm. These data indicate that the cell bodies of origin of the mesocortical dopaminergic system are activated by stress in contrast to those DA neurons innervating the striatum. It appears that mesocortical dopaminergic neurons exhibit different regulatory features than mesolimbic or nigrostriatal neurons.

The administration of baclofen to mice increases 5-HT2-mediated head-twitch behaviour and 5-HT2 receptor number in frontal cortex

Mice were injected with baclofen (10 mg/kg) and then given baclofen in drinking water (10 mg/kg/day). After 1 day of administration of baclofen the head-twitch response to the precursor 5-hydroxytryptophan (5-HTP) was reduced but the response to the agonist 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) was unaltered. However, after 14 days the head-twitch response to both 5-HTP and 5-MeODMT was enhanced and this enhancement was present for 14 days after drug withdrawal. After 14 days of administration of baclofen the number of 5-HT2 receptor binding sites in frontal cortex (labelled by [3H]-ketanserin) was also elevated. It is suggested that the enhanced 5-HT2 function, following longer-term administration of baclofen is the consequence of the drug inhibiting 5-HT release in vivo, as indicated by the observations after acute administration.

Neurotensin immunoreactivity in post-mortem brain is increased in Down's syndrome but not in Alzheimer-type dementia

Neurotensin immunoreactivity and choline acetyltransferase (ChAT) activity were measured in post-mortem brain from 10 cases of Down's syndrome (7 aged 53-63 years, one aged 27 years, one aged 16 months and one aged 10 months), 6 cases of Alzheimer-type dementia (ATD) and 19 control subjects (13 aged 40-88 years and 6 aged 9-18 months). Neurotensin concentrations in anterior and basal hypothalamus, amygdala, septal area, caudate nucleus and temporal cortex were unaltered in ATD. The concentrations of neurotensin were significantly increased in the caudate nucleus, temporal cortex and frontal cortex in the cases of Down's syndrome aged 53-63 years with the neuropathological features of ATD, and were also increased in the cerebral cortex of the 27-year-old, which did not have the neuropathological features of ATD, and in two infant Down's cases. ChAT activity was reduced in the ATD and the 53-63-year-old cases of Down's syndrome, but not in the 27-year or 10-month-old Down's cases. The increased neurotensin concentrations appear to be a feature of Down's syndrome not related to the presence of plaques and neurofibrillary tangles or to a deficit in ChAT activity.

Adrenergic receptors in frontal cortex in human brain

The binding of three adrenergic ligands ([3H]prazosin, [3H]clonidine, [3H]dihydroalprenolol) was studied in the frontal cortex of human brain. alpha 1-Receptors, labeled by [3H]prazosin, predominated. [3H]Clonidine bound to two classes of sites, one of high affinity and one of low affinity. Guanosine triphosphate appeared to lower the affinity of [3H]clonidine for its receptor. [3H]Dihydroalprenolol bound to three classes of sites: the beta 1-receptor, the beta 2-receptor and a receptor with low affinity which represented about 40% of the total binding, but which was probably a non-specific site; the beta 1/beta 2 ratio was 1/2.

Early postnatal handling alters glucocorticoid receptor concentrations in selected brain regions

Norway rat pups were either handled (H) or undisturbed (nonhandled, NH) in the period between birth and weaning on Day 21. Following weaning, half of the animals in each group were housed socially (Soc), and half were housed in isolation (Isol). At 120-150 days of age, all animals were sacrificed, and the following regions were dissected and frozen at -70 degrees C until the time of assay: frontal cortex, hippocampus, hypothalamus, amygdala, septum, and pituitary. [3H]Dexamethasone (3H Dex) binding in each region was examined by an in vitro, cytosol, receptor assay. 3H Dex binding was significantly higher in the hippocampus of both H-Soc and H-Isol than in NH groups. In the frontal cortex, 3H Dex binding was higher in the H-Soc animals than in the H-Isol and NH-Isol animals. There were no significant handling or housing effects found in the amygdala, hypothalamus, septum, or pituitary. Thus, early postnatal handling appears to influence the development of the glucocorticoid receptor system in the hippocampus and frontal cortex. These results are discussed as providing a possible mechanism for some of the previously reported effects of early handling on the development of the pituitary-adrenal response to stress.

Cholinergic receptor binding in the frontal cortex of suicide victims

Muscarinic binding sites were assessed in the frontal cortex of 22 suicide victims and 22 control subjects. There were no significant differences between the two groups in either the number of binding sites (Bmax) or their relative affinity (Kd). The results of this study are discussed in reference to the cholinergic hypothesis of affective disorders.